BioNotebook: NPS gets orphan status in Europe, Neuralstem raises $20 million, Salix completes buyout of Santarus
This article was originally published in Scrip
Executive Summary
NPS Pharmaceuticals gets an orphan drug designation for it hormone disorder treatment Natpara in the EU. Stem cell company Neuralstem raises almost $20 million in a stock sale, and Salix Pharmaceuticals said it wrapped up its deal for rival Santarus.